Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease

Bibliography

• de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5:525-35
   PubMed Web of Science ®Google Scholar
• Willis AW. Parkinson disease in the elderly adult. Mo Med 2013;110:406-10
   PubMedGoogle Scholar
• Boeve BF. Idiopathic REM sleep behaviour disorder in the development of Parkinson’s disease. Lancet Neurol 2013;12:469-82
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Goldstein DS. Autonomic dysfunction in Parkinson disease. Handb Clin Neurol 2013;117:259-78
   PubMedGoogle Scholar
• Maass A, Reichmann H. Sleep and non-motor symptoms in Parkinson’s disease. J Neural Transm 2013;120:565-9
   PubMed Web of Science ®Google Scholar
• Olanow CW, Stocchi F, Lang A. Parkinson’s disease: non-motor and non-dopaminergic features. Wiley-Blackwell; Hoboken, NJ, USA: 2011
   Google Scholar
• Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 2004;318:121-34
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord 2012;27:8-30
   PubMed Web of Science ®Google Scholar
• Olanow CW. The pathogenesis of cell death in Parkinson’s disease. Mov Disord 2007;17:S335-42
   Google Scholar
• Suchowersky O, Gronseth G, Perlmutter J, et al. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:976-82
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. The Parkinson Study Group. N Engl J Med 1993;328:176-83
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-61
   PubMed Web of Science ®Google Scholar
• Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson’s disease. Parkinsonism Relat Disord 2002;8:271-6
   PubMed Web of Science ®Google Scholar
• Shults C W, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50
   PubMed Web of Science ®Google Scholar
• Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-6
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004;351:2498-08
   PubMed Web of Science ®Google Scholar
• NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664-71
   PubMed Web of Science ®Google Scholar
• Tilley BC, Galpern WR. Screening potential therapies: lessons learned from new paradigms used in Parkinson disease. Stroke 2007;2 Suppl):800-3
   PubMed Web of Science ®Google Scholar
• NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68:20-8
   PubMed Web of Science ®Google Scholar
• Olanow C W, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361:1268-78
   PubMed Web of Science ®Google Scholar
• Stocchi F and Olanow CW. Obstacles to the development of a neuroprotective therapy for Parkinson’s disease. Mov Disord 2013;28:3-7
   PubMed Web of Science ®Google Scholar
• Dorszewska J, Prendecki M, Lianeri M, Kozubski W. Molecular Effects of L-dopa Therapy in Parkinson’s Disease. Curr Genomics 2014;11-17
   PubMed Web of Science ®Google Scholar
• Müller T, Muhlack S. Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson’s disease patients. Mov Disord 2011;543-6
   PubMed Web of Science ®Google Scholar
• Müller T, Muhlack S. Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson’s disease patients. J Neural Transm 2014;643-8
   PubMed Web of Science ®Google Scholar
• Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998;561-75
   PubMed Web of Science ®Google Scholar
• Schapira AH. “The clinical relevance of levodopa toxicity in the treatment of Parkinson’s disease”. Mov Disord 2008;23:S515-20
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA. Parkinson disease: the controversy of levodopa toxicity in Parkinson disease. Nat Rev Neurol 2012;8:8-10
   Web of Science ®Google Scholar
• Müller T, Jugel C, Muhlack S, Klostermann F. Methyl group-donating vitamins elevate 3-O-methyldopa in patients with Parkinson disease. Clin Neuropharmacol 2013;52-4
   PubMed Web of Science ®Google Scholar
• Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson’s disease, insulin resistance and novel agents of neuroprotection. Brain 2013;374-84
   PubMed Web of Science ®Google Scholar
• Lima MM, Targa AD, Noseda AC, et al. Does Parkinson’s disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments? CNS Neurol Disord Drug Targets 2014;418-28
   PubMed Web of Science ®Google Scholar
• Santiago JA, Potashkin JA. Shared dysregulated pathways lead to Parkinson’s disease and diabetes. Trends Mol Med 2013;176-86
   PubMed Web of Science ®Google Scholar
• Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson’s disease. Diabetes Care 2011;910-15
   PubMed Web of Science ®Google Scholar
• Cereda E, Barichella M, Cassani E, et al. Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology 2012;1507-11
   PubMed Web of Science ®Google Scholar
• Santiago JA, Potashkin JA. System-based approaches to decode the molecular links in Parkinson’s disease and diabetes. Neurobiol Dis 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Shin JH, Ko HS, Kang H, et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson’s disease. Cell 2011;144:689-702
   PubMed Web of Science ®Google Scholar
• Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003;34(3):267-73
   PubMed Web of Science ®Google Scholar
• Zheng B, Liao Z, Locascio JJ, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med 2010;2:52ra73
   PubMed Web of Science ®Google Scholar
• Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med (Berl) 2004;82:510-29
   PubMed Web of Science ®Google Scholar
• Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson’s disease. J Clin Invest 2013;123:2730-6
   PubMed Web of Science ®Google Scholar
• Chaturvedi RK, Beal MF. PPAR: a therapeutic target in Parkinson’s disease. J Neurochem 2008;106:506-18
   PubMed Web of Science ®Google Scholar
• Nicolakakis N, Aboulkassim T, Ongali B, et al. Complete rescue of cerebrovascular function in aged Alzheimer’s disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 2008;28:9287-96
   PubMed Web of Science ®Google Scholar
• Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J 2006;6:246-54
   PubMed Web of Science ®Google Scholar
• Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-a-b/d and -c in the adult rat. Endocrinology 1996;137:354-66
   PubMed Web of Science ®Google Scholar
• Mukherjee R, Jow L, Croston GE, Paterniti JR. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARc2 versus PPARc1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997;272:8071-6
   PubMed Web of Science ®Google Scholar
• Varga T, Czimmerer Z, Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta 2011;1812:1007-22
   PubMed Web of Science ®Google Scholar
• Cimini A, Benedetti E, Cristiano L, et al. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors RXRs in rat cortical neurons. Neuroscience 2005;130:325-37
   PubMed Web of Science ®Google Scholar
• Moreno S, Farioli-Vecchioli S, Cerù MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid receptors in the adult rat CNS. Neuroscience 2004;123:131-45
   PubMed Web of Science ®Google Scholar
• Carta AR, Frau L, Pisanu A, et al. Rosiglitazone decreases peroxisome proliferator receptor-c levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson’s disease model. Neuroscience 2011;194:250-61
   PubMed Web of Science ®Google Scholar
• Sarruf DA, Yu F, Nguyen HT, et al. Expression of peroxisome proliferator-activated receptor-c in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 2009;150:707-12
   PubMed Web of Science ®Google Scholar
• Swanson C, Emborg M. Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates. Neurol Res 2014;36(7):634-46
   PubMed Web of Science ®Google Scholar
• Bernardo A, Minghetti L. Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists. PPAR Res 2008;2008:864140
   PubMed Web of Science ®Google Scholar
• Ricote M, Glass CK. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 2007;1771:926-35
   PubMed Web of Science ®Google Scholar
• Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-88
   PubMed Web of Science ®Google Scholar
• Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007;447:1116-20
   PubMed Web of Science ®Google Scholar
• Pascual G, Sullivan AL, Ogawa S, et al. Anti-inflammatory and antidiabetic roles of PPARgamma. Novartis Found Symp 2007;286:183-96
   PubMedGoogle Scholar
• Satoh N, Shimatsu A, Himeno A, et al. Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone. Diabetes Care 2010;33:e7
   PubMedGoogle Scholar
• Carta AR. PPAR-gamma: therapeutic prospects in Parkinson’s disease. Curr Drug Targets 2013;14:743-51
   PubMed Web of Science ®Google Scholar
• Heneka MT, Landreth GE, Hϋll M. Drug insight: effects mediated by peroxisome proliferator-activated receptor-c in CNS disorders. Nat Clin Pract Neurol 2007;3:496-504
   PubMedGoogle Scholar
• Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 2008;13:1813-26
   PubMed Web of Science ®Google Scholar
• Breidert T, Callebert J, Heneka MT, et al. Protective action of the peroxisome proliferatoractivated receptor-gamma agonist pioglitazone in a mouse model of Parkinson’s disease. J Neurochem 2002;82:615-24
   PubMed Web of Science ®Google Scholar
• Dehmer T, Heneka MT, Sastre M, et al. Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 2004;88:494-01
   PubMed Web of Science ®Google Scholar
• Hunter RL, Choi DY, Ross SA, Bing G. Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett 2008;432:198-201
   PubMed Web of Science ®Google Scholar
• Kumar P, Kaundal RK, More S, Sharma SS. Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson’s disease. Behav Brain Res 2009;197:398-403
   PubMed Web of Science ®Google Scholar
• Swanson CR, Joers V, Bondarenko V, et al. The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation 2011;8:91
   PubMed Web of Science ®Google Scholar
• Swanson CR, Du E, Johnson DA, et al. Neuroprotective properties of a novel non-thiazoledinedione partial PPAR-gamma agonist against MPTP. PPAR Res 2013;2013:582809
   PubMed Web of Science ®Google Scholar
• Schintu N, Frau L, Ibba M, et al. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson’s disease. Eur J Neurosci 2009;29:954-63
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Kahn SE, Zinman B, Lachin JM, Haffner SM, et al. Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-51
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al. RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35
   PubMed Web of Science ®Google Scholar
• US FDA. Available from: www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM226959.pdf
   Google Scholar
• US FDA. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm
   Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8
   PubMed Web of Science ®Google Scholar
• Barbalat Y, Dombrovskiy VY, Weiss RE. Association between pioglitazone and urothelial bladder cancer. Urology 2012;80:1-4
   PubMed Web of Science ®Google Scholar
• Bosetti C, Rosato V, Buniato D, et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 2013;18:148-56
   PubMed Web of Science ®Google Scholar
• Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012;184:E675-83
   PubMed Web of Science ®Google Scholar
• Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med 2013;30:1026-32
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Elisaf MS, Mikhailidis DP. Pioglitazone and cancer: angel or demon? Curr Pharm Des 2013;19:4913-29
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Mannucci E. Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials. Acta Diabetol 2014;51:91-101
   PubMed Web of Science ®Google Scholar
• Turner RM, Kwok CS, Chen-Turner C, et al. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol 2014;78(2):258-73
   Google Scholar
• Zhu Z, Shen Z, Lu Y, et al. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2012;98:159-63
   PubMed Web of Science ®Google Scholar
• Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012;344:e3645
   PubMed Web of Science ®Google Scholar
• Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst 2012;104:1411-21
   PubMed Web of Science ®Google Scholar
• Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012;55:1953-62
   PubMed Web of Science ®Google Scholar
• Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34:916-22
   PubMed Web of Science ®Google Scholar
• Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012;35:278-80
   PubMed Web of Science ®Google Scholar
• Vallarino C, Perez A, Fusco G, et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig 2013;33:621-31
   PubMed Web of Science ®Google Scholar
• Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 2013;75:254-9
   PubMed Web of Science ®Google Scholar
• Cohen SM. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci 2005;87:322-7
   PubMed Web of Science ®Google Scholar
• Suzuki S, Arnold LL, Pennington KL, et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci 2010;113:349-57
   PubMed Web of Science ®Google Scholar
• Tseng CH, Tseng FH. Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2012;30:368-402
   PubMed Web of Science ®Google Scholar
• Varley CL, Stahlschmidt J, Smith B, et al. Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am J Pathol 2004;164:1789-98
   PubMed Web of Science ®Google Scholar
• Pioglitazone in Early Parkinson’s Disease. 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01280123
   Google Scholar
• Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease. J Parkinsons Dis 2014;4(3):337-44
   PubMedGoogle Scholar